Business Context and Reporting Period
Company: Avalo Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: August 6, 2026
Reporting Period: Quarter ended June 30, 2026
Context: The filing serves as a notification that the company issued a press release announcing its financial results for the second quarter of 2026. The press release is included as Exhibit 99.1.
Key Financial Metrics
The provided text is a cover page and index for the Form 8-K. It references the existence of financial results in an attached press release (Exhibit 99.1) but does not contain the specific data points within the text itself.
- Revenue: Not provided in the filing text.
- Profit/Loss: Not provided in the filing text.
- Cash Flow: Not provided in the filing text.
- Margins: Not provided in the filing text.
- Debt and Liquidity: Not provided in the filing text.
Material Changes
The filing text does not provide specific numerical comparisons or descriptions of material changes versus the prior comparable period. Investors must refer to the attached press release (Exhibit 99.1) for this information.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, forward-looking guidance, specific risk factors, or details on contingencies and unusual items. These disclosures are contained within the referenced press release.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated August 6, 2026) for actual revenue, net loss, and cash position figures.
- Verify the company's cash runway and burn rate as disclosed in the full press release.
- Check for any updates on clinical trial progress or regulatory milestones mentioned in the press release.
- Confirm if the company has issued any forward-looking guidance for the remainder of 2026.